The interview series with Algernon Pharmaceuticals CEO Christopher Moreau and PRmediaNow host Cyndi Edwards continues. In today’s episode, Mr. Moreau discusses recent news regarding the company’s preclinical study of the psychedelic drug DMT for the treatment of Stroke using a sub-hallucinogenic dose, which increased the growth of neurons in the brain by 40%.